Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 5, 1997, Pages 410-416

  Vail, David M ^a,b   Kravis, Laura D ^a   Cooley, A James ^a   Chun, Ruthanne ^a   MacEwen, E Gregory ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Canine; Doxil; Doxorubicin; Liposomes; PPES

Indexed keywords

DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; DOG; DRUG TOLERABILITY; ENCAPSULATION; FEMALE; GASTROINTESTINAL TOXICITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SKIN TOXICITY; TACHYCARDIA; TOXICITY TESTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOG DISEASES; DOGS; DOXORUBICIN; DRUG CARRIERS; FEMALE; GASTROINTESTINAL DISEASES; LIPOSOMES; MALE; NEOPLASMS; ORCHIECTOMY; OVARIECTOMY; PROSPECTIVE STUDIES; SKIN;

EID: 0031047788     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050591     Document Type: Article

References (28)

1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32:302
2. Ogilvie GK, Richardson RC, Curtis CR, Withrow SJ, Reynolds HA, Morris AM, Henderson RA, Klausner JS, Fowler JD, McCaw D (1989) Acute and short-term toxicoses associated with the administration of doxorubicin to dogs with malignant tumors. J Am Vet Med Assoc 195:1584
3. Tahman A, More N, Schein PS (1982) Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res 42: 1817
4. Gabizon A, Meshorer A, Barenholz Y (1986) Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. J Natl Cancer Inst 77:459
5. Rahman A. Fumagalli A, Goodman A, Schein PS (1984) Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 11:45
6. Balazsovits JAE, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE (1989) Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23:81
7. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP (1993) Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 7:17
8. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A (1991) Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochem Biophys Acta 1066:29
9. Allen TM, Hansen C (1991) Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochem Biophys Acta 1068:133
10. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 54:987
11. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, Ben-Dor CG, Rabello E, Cass Y, Peretz T, Sulkes A, Chisin R, Barenholz Y (1994) Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 33:779
12. Vaage J, Donovan D, Mayhew E, Abra R, Huang A (1993) Therapy of human ovarian carcinoma xenographs using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 72:3671
13. Gabizon AA, Barenholz Y, Bialer M (1993) Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res 10:703
14. Owen LN (ed) (1980) World Health Organization TNM classification of tumors in domestic animals. 1st edn. WHO, Geneva
15. Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE (1992) Evaluation of prognostic factors and sequential combination chemotherapy for canine lymphoma. J Vet Intern Med 7:289
16. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A (1995) Liposomal doxorubicin: antilumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13:1777
17. Leichman CG, Leichman L, Spears CP, Rosen PJ, Jeffers S, Groshen S (1993) Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst 85:41
18. Grem JL, McAtee N, Balis F, Murphy R, Venzon D, Kramer B, Goldspiel B, Begley M, Allegra CJ (1993) A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 72:663
19. Samuals BL, Vogelzang NJ, Ruane M, Simon MA (1987) Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 71:971
20. Matsuyama JR, Kwok KK (1989) A variant of the chemotherapy-associated erythrodysesthesia syndrome related to high-dose cyclophosphamide. DICP 23:778
21. Lodich JJ, Moore C (1984) Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 101:798
22. Zimmerman GC, Keeling JH, Lowry M, Medina J, Von Hoff DD, Burris HA (1994) Prevention of docetaxel induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst 86:557
23. Vukelja SJ, Lombardo FA, James WD, Weiss RB (1989) Pyroxidine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 111:688
24. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R (1990) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 8:57
25. Vukelja SJ, Baker WJ, Burris HA, Keeling JH, Von Hoff D (1993) Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 85:1432
26. Newman MS, Amentea MA, Sullivan TM, Forrest A, Working PK (1996) Pharmacokinetics/pharmacodynamics of pegylated-liposomal doxorubicin and the appearance of dermal lesions in dogs (abstract). Clin Pharmacol Ther 59(2), abstract no. 96:153
27. Ogilvie GK, Reynolds HA, Richardson RC, Withrow SJ, Norris AM, Henderson RA, Klausner JS, Fowler JD, McCaw D (1989) Phase II evaluation of doxorubicin for treatment of various canine neoplasms. J Am Vet Med Assoc 195:1580
28. Ogilvie GK, Obradovich JE, Elmslie RE, Vail DM, Moore AS, Straw RC, Dickinson K, Cooper MF, Withrow SJ (1991) Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc 198:1618